他に治療法がない膿疱性乾癬の増悪患者にスペソリマブを提供するための日本での拡大アクセス試験

基本情報

NCT ID

NCT05200247

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

11

治験依頼者名

Boehringer Ingelheim

概要

This Expanded Access trial in Japan is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP). This program provides a medicine called spesolimab to people with a GPP flare-up who have no alternative treatment options. Participants get a single infusion of spesolimab into a vein. They can get another spesolimab infusion one week after the first infusion if the doctors think it is helpful. Participants are in the program for about 4 months and visit the study site about 5 to 6 times. The doctors regularly check participants' health and take note of any unwanted effects.

対象疾患

介入

依頼者（Sponsor）

実施施設 (9)